Download Files:

Sunvozertinib

SKU T64124-1 mL * 10 mM (in DMSO) Category Small Compound Brand: TargetMol

Price range: 48 CAD through 2,336 CAD

For Research Use Only (RUO). This product is sold strictly for laboratory research use. Not for human or veterinary consumption, therapeutic, or diagnostic use.For sale to research organizations and laboratories only; not for patients or for personal use.

Size

1 mg 1 mL * 10 mM (in DMSO)10 mg 100 mg 25 mg 5 mg 50 mg 500 mg

Clear

Products Details

Product Description

– Sunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor, with inhibitory effects on EGFR, Her2, and mutant epidermal growth factor. Sunvozertinib (DZD9008) showed inhibitory effects on EGFR exon 20 NPH insertion, EGFR exon 20 ASV insertion, EGFR L858R and T790M mutations, as well as Her2 exon 20 YVMA and EGFR WT A431 with IC50 of 20.4, 20.4, 1.1, 7.5, and 80.4 nM.

For Research Use Only (RUO). This product is sold strictly for laboratory research use only. Not for human or veterinary consumption, therapeutic, or diagnostic use. Any pharmacological, therapeutic, cosmetic, or biological effects described above are provided as research context only and do not represent intended or approved uses of this product.

Web ID

– T64124

Storage Temperature

– -20℃

Shipping

– Blue Ice

Molecular Formula

– C29H35ClFN7O3

References

– Zhengtao LI, et al. Erbb/btk inhibitors. WO2019149164A1.

CAS Number

– 2370013-12-8

Molecular Weight

– C29H35ClFN7O3

Compound Purity

– 0.9971

SMILES

– COc1cc(N2CC[C@H](C2)N(C)C)c(NC(=O)C=C)cc1Nc1nccc(Nc2cc(Cl)c(F)cc2C(C)(C)O)n1

Pathway

– Tyrosine Kinase/Adaptors|||JAK/STAT signaling|||Angiogenesis

Product type

– Small Compound

Booklet

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.